Literature DB >> 10391695

U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.

J D Berman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10391695     DOI： 10.1086/515086

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  10 in total

1.  US Food and Drug Administration Approval of Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis: A Model for Orphan Drug Development.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.725

2.  Leishmaniasis at the End of the Millennium.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.725

3.  Cutaneous leishmaniasis in Cuban immigrants to Texas who traveled through the Darién Jungle, Panama.

Authors:  Meagan A Barry; Misha V Koshelev; Grace S Sun; Sarah J Grekin; Charles E Stager; A Hafeez Diwan; Carina A Wasko; Kristy O Murray; Laila Woc-Colburn
Journal:  Am J Trop Med Hyg       Date:  2014-05-27       Impact factor: 2.345

4.  Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region.

Authors:  F Pasquau; J Ena; R Sanchez; J M Cuadrado; C Amador; J Flores; C Benito; C Redondo; J Lacruz; V Abril; J Onofre
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

5.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05

Review 6.  Liposomal amphotericin B as a treatment for human leishmaniasis.

Authors:  Manica Balasegaram; Koert Ritmeijer; Maria Angeles Lima; Sakib Burza; Gemma Ortiz Genovese; Barbara Milani; Sara Gaspani; Julien Potet; François Chappuis
Journal:  Expert Opin Emerg Drugs       Date:  2012-11-20       Impact factor: 4.191

7.  Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.

Authors:  Saumya Srivastava; Jyotsna Mishra; Anil Kumar Gupta; Amit Singh; Prem Shankar; Sarman Singh
Journal:  Parasit Vectors       Date:  2017-01-31       Impact factor: 3.876

8.  Application of magnetically induced hyperthermia in the model protozoan Crithidia fasciculata as a potential therapy against parasitic infections.

Authors:  V Grazú; A M Silber; M Moros; L Asín; T E Torres; C Marquina; M R Ibarra; G F Goya
Journal:  Int J Nanomedicine       Date:  2012-10-08

Review 9.  Optimizing efficacy of amphotericin B through nanomodification.

Authors:  Suresh P Vyas; Swati Gupta
Journal:  Int J Nanomedicine       Date:  2006

Review 10.  Strategies to overcome antileishmanial drugs unresponsiveness.

Authors:  Shyam Sundar; Anup Singh; Om Prakash Singh
Journal:  J Trop Med       Date:  2014-04-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.